Vantage Investment Partners Upped Jpmorgan Chase & Co (JPM) Position; Inovio Pharmaceuticals (INO) Shorts Lowered By 3.93%

November 14, 2017 - By Clifton Ray

Vantage Investment Partners Llc increased Jpmorgan Chase & Co (JPM) stake by 215.2% reported in 2017Q2 SEC filing. Vantage Investment Partners Llc acquired 286,676 shares as Jpmorgan Chase & Co (JPM)’s

stock declined 6.04%. The Vantage Investment Partners Llc holds 419,892 shares with $38.38M value, up from 133,216 last quarter. Jpmorgan Chase & Co now has $337.50B valuation. The stock decreased 0.58% or $0.57 during the last trading session, reaching $97.27. About 9.99 million shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since November 14, 2016 and is uptrending. It has outperformed by 17.04% the S&P500.

Inovio Pharmaceuticals Incorporated (NASDAQ:INO) had a decrease of 3.93% in short interest. INO’s SI was 8.59 million shares in November as released by FINRA. Its down 3.93% from 8.94 million shares previously. With 1.02 million avg volume, 8 days are for Inovio Pharmaceuticals Incorporated (NASDAQ:INO)’s short sellers to cover INO’s short positions. The SI to Inovio Pharmaceuticals Incorporated’s float is 12.49%. The stock decreased 5.27% or $0.24 during the last trading session, reaching $4.31. About 1.68M shares traded or 38.84% up from the average. Inovio Pharmaceuticals Inc (NASDAQ:INO) has declined 29.01% since November 14, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Investors sentiment increased to 1.19 in Q2 2017. Its up 0.32, from 0.87 in 2017Q1. It improved, as 56 investors sold JPM shares while 678 reduced holdings. 146 funds opened positions while 731 raised stakes. 2.69 billion shares or 4.21% more from 2.58 billion shares in 2017Q1 were reported. Cubist Systematic Strategies Lc reported 0.05% stake. 1St Glob Advsr Incorporated holds 0.42% or 39,660 shares. Moreover, Dana Investment Advsrs has 1.75% invested in JPMorgan Chase & Co. (NYSE:JPM) for 406,650 shares. Wealthtrust Axiom Lc invested in 0.11% or 3,233 shares. Sigma Counselors stated it has 67,478 shares or 0.95% of all its holdings. Qcm Cayman Limited has 0.63% invested in JPMorgan Chase & Co. (NYSE:JPM) for 3,033 shares. Osterweis Cap Mgmt holds 2.16% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM) for 309,795 shares. Midas Mngmt reported 8,200 shares stake. Markel Corporation holds 0.36% or 183,000 shares in its portfolio. Kimelman And Baird Limited Co owns 287,109 shares. 10,191 are owned by Atwood Palmer Inc. Public Employees Retirement Association Of Colorado stated it has 2.21 million shares or 1.49% of all its holdings. Dowling & Yahnke Limited Company, a California-based fund reported 100,333 shares. Trust Communications Of Oklahoma has invested 0% in JPMorgan Chase & Co. (NYSE:JPM). Mai Mngmt holds 1.31% or 223,041 shares in its portfolio.

Among 32 analysts covering JPMorgan Chase & Co (NYSE:JPM), 17 have Buy rating, 2 Sell and 13 Hold. Therefore 53% are positive. JPMorgan Chase & Co had 86 analyst reports since July 21, 2015 according to SRatingsIntel. BMO Capital Markets maintained JPMorgan Chase & Co. (NYSE:JPM) on Friday, July 14 with “Hold” rating. Keefe Bruyette & Woods maintained the shares of JPM in report on Wednesday, October 11 with “Hold” rating. The rating was upgraded by Credit Agricole on Tuesday, August 25 to “Outperform”. Argus Research maintained it with “Buy” rating and $70.0 target in Friday, January 15 report. On Tuesday, January 3 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was reinitiated by UBS with “Buy” on Wednesday, January 11. Jefferies maintained the shares of JPM in report on Wednesday, October 7 with “Buy” rating. The company was maintained on Wednesday, August 12 by Deutsche Bank. Ertse Group downgraded JPMorgan Chase & Co. (NYSE:JPM) on Monday, April 25 to “Hold” rating. The firm has “Buy” rating by Bank of America given on Sunday, July 16.

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals had 33 analyst reports since August 10, 2015 according to SRatingsIntel. As per Wednesday, August 12, the company rating was downgraded by Zacks. As per Wednesday, September 6, the company rating was initiated by Citigroup. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, September 12. The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) has “Buy” rating given on Tuesday, August 8 by Stifel Nicolaus. Piper Jaffray maintained the stock with “Overweight” rating in Monday, August 10 report. Maxim Group downgraded the shares of INO in report on Tuesday, August 9 to “Hold” rating. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 9. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, May 25 report. The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) has “Buy” rating given on Monday, June 26 by Stifel Nicolaus. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, October 17.

Inovio Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has market cap of $389.18 million. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It currently has negative earnings. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>